Nipah virus: a summary for clinicians
Dublin Core
Title
Nipah virus: a summary for clinicians
Subject
of a series on acute, severe diseases of humans caused by emerging viruses for which
there are limited or no licensed medical countermeasures.
there are limited or no licensed medical countermeasures.
Description
Abstract
Objectives This article is one of a series on acute, severe diseases of humans caused by emerging viruses for which
there are limited or no licensed medical countermeasures. Nipah virus (NiV) is recognized as a pathogen of concern
by health experts and is included on the WHO list of emerging pathogens with pandemic concern. However, NiV is a
relatively poorly understood pathogen, due to the small number of outbreaks and human clinical studies. The primary
objective of this summary on NiV is to provide a global understanding of clinical perspectives, providing overviews of
pathogenesis, clinical features, and diagnostics while emphasizing medical countermeasures. The focus is on potential
therapies and vaccines that have demonstrated potential efficacy to combat NiV infection to provide clinicians
candidates for use in an emergency situation or clinical research settings.
Methods A literature review was conducted for NiV vaccines and therapeutics tested in animal models of disease.
Results We identified two antiviral medications approved by the U.S. FDA with potential benefit for the off-label
treatment of NiV infection, and a larger number of potential candidates are currently being evaluated in early
development. Multiple vaccine platforms are in pre-clinical development for NiV prevention, but data from human
clinical trials are not yet available.
Conclusion We provide specific background information on NiV and disease manifestations along with succinct
summaries of medical countermeasures against NiV to provide clinicians a rapid reference to review the literature if
faced with a patient in whom NiV infection is suspected. Moreover, the information provides several candidates for
human clinical research studies in outbreak settings.
Objectives This article is one of a series on acute, severe diseases of humans caused by emerging viruses for which
there are limited or no licensed medical countermeasures. Nipah virus (NiV) is recognized as a pathogen of concern
by health experts and is included on the WHO list of emerging pathogens with pandemic concern. However, NiV is a
relatively poorly understood pathogen, due to the small number of outbreaks and human clinical studies. The primary
objective of this summary on NiV is to provide a global understanding of clinical perspectives, providing overviews of
pathogenesis, clinical features, and diagnostics while emphasizing medical countermeasures. The focus is on potential
therapies and vaccines that have demonstrated potential efficacy to combat NiV infection to provide clinicians
candidates for use in an emergency situation or clinical research settings.
Methods A literature review was conducted for NiV vaccines and therapeutics tested in animal models of disease.
Results We identified two antiviral medications approved by the U.S. FDA with potential benefit for the off-label
treatment of NiV infection, and a larger number of potential candidates are currently being evaluated in early
development. Multiple vaccine platforms are in pre-clinical development for NiV prevention, but data from human
clinical trials are not yet available.
Conclusion We provide specific background information on NiV and disease manifestations along with succinct
summaries of medical countermeasures against NiV to provide clinicians a rapid reference to review the literature if
faced with a patient in whom NiV infection is suspected. Moreover, the information provides several candidates for
human clinical research studies in outbreak settings.
Creator
Corri B. Levine1
, Lauren M. Sauer2
, Susan L. F. McLellan1
, Jared D. Evans2,3* and On behalf of the State of the
Science Working Group of the National Ebola Training and Education Center’s (NETEC’s) Special Pathogens
Research Network (SPRN)
, Lauren M. Sauer2
, Susan L. F. McLellan1
, Jared D. Evans2,3* and On behalf of the State of the
Science Working Group of the National Ebola Training and Education Center’s (NETEC’s) Special Pathogens
Research Network (SPRN)
Source
https://doi.org/10.1186/s12245-025-00916-1
Date
2025
Contributor
Peri Irawan
Format
pdf
Language
english
Type
text
Files
Collection
Citation
Corri B. Levine1
, Lauren M. Sauer2
, Susan L. F. McLellan1
, Jared D. Evans2,3* and On behalf of the State of the
Science Working Group of the National Ebola Training and Education Center’s (NETEC’s) Special Pathogens
Research Network (SPRN), “Nipah virus: a summary for clinicians,” Repository Horizon University Indonesia, accessed April 26, 2026, https://repository.horizon.ac.id/items/show/12828.